- KR₩145bn
- KR₩143bn
- KR₩57bn
Brief: Isu Abxis Q2 Operating Profit 9.4 Billion Won, Up 97% From Year Earlier
Brief: Isu Abxis Q2 Operating Profit 4.8 Billion Won, Up 5708.5% From Year Earlier
Brief: Isu Abxis Wins 10.5 Billion Won Order
Brief: Isu Abxis Q1 Operating Profit 3 Billion Won, Swings To Profit From Year Earlier
Brief: Isu Abxis Q3 Operating Profit 2 Billion Won, Swings To Profit From Year Earlier
Brief: Isu Abxis Wins 11 Billion Won Order
Brief: Isu Abxis Q2 Operating Profit 82 Million Won, Up 116.6% From Year Earlier
Brief: Isu Abxis Co Wins 3.2 Billion Won Order
Brief: Catalyst Biosciences Says On Dec 13, Co Entered Into Amended & Restated License Agreement Effective As Of Dec 17, 2018, With Isu Abxis
Brief: ISU Abxis raises 28.08 bln won via rights issue
Brief: Catalyst Biosciences gets IND approval in South Korea for subcutaneous factor IX program
Brief: ISU Abxis appoints Lee Seok Ju as CEO
Brief: ISU Abxis signs contract worth 1.06 bln won
Brief: Isu Abxis says change of CEO to Kim Muk from Kim Dae Sung